Simulations Plus (NASDAQ:SLP – Get Free Report) released its earnings results on Wednesday. The technology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02, Briefing.com reports. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The firm had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the prior year, the firm posted $0.18 earnings per share. The company’s quarterly revenue was up 19.9% on a year-over-year basis. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.
Simulations Plus Stock Down 0.9 %
SLP stock traded down $0.28 during trading on Friday, hitting $30.68. 276,597 shares of the company’s stock traded hands, compared to its average volume of 130,076. The firm has a market capitalization of $613.91 million, a P/E ratio of 64.50 and a beta of 0.69. Simulations Plus has a 1 year low of $29.37 and a 1 year high of $51.22. The business has a fifty day simple moving average of $33.20 and a two-hundred day simple moving average of $40.76.
Insiders Place Their Bets
In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $31.26, for a total value of $625,200.00. Following the completion of the transaction, the director now directly owns 3,481,592 shares of the company’s stock, valued at approximately $108,834,565.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 60,750 shares of company stock worth $2,145,055 over the last 90 days. Company insiders own 20.90% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Analysis on SLP
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Further Reading
- Five stocks we like better than Simulations Plus
- What is a Dividend King?
- Texas Roadhouse Stock Steering for New Highs This Year
- How Can Investors Benefit From After-Hours Trading
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.